CureVac Completes Stock Delisting Following BioNTech Acquisition

The publicly traded chapter for CureVac has officially closed. The mRNA specialist’s shares have ceased trading on public exchanges after BioNTech successfully finalized its acquisition of the company. Investors seeking exposure to CureVac’s assets and technology must now do so through BioNTech’s stock.

A Strategic Merger Finalized

The technical completion of this corporate merger marks the end of CureVac’s independent market presence. BioNTech wrapped up the acquisition through a post-offer reorganization on January 6, 2026. Subsequently, the formal delisting from the Nasdaq Global Market took effect on January 16.

This process originated from a merger agreement initially announced in June 2025. During the public exchange offer, which ran from October to December 2025, a total of 195,341,219 CureVac shares were tendered by shareholders. According to the settlement agent, Computershare, this figure represented approximately 86.75% of all outstanding shares.

Transaction Mechanics and Valuation

Structured as an all-stock deal, the transaction placed an enterprise value of roughly $1.25 billion on CureVac. Shareholders who participated in the offer received BioNTech American Depositary Shares (ADS) based on a predetermined exchange ratio.

To gain full ownership, BioNTech also executed a statutory squeeze-out procedure to acquire the remaining minority interests. The legal merger resulted in CureVac Merger B.V. becoming the successor entity to CureVac N.V., thereby eliminating any remaining outside shareholders.

Should investors sell immediately? Or is it worth buying CureVac?

Key Transaction Details:
* Offer Acceptance Deadline: December 18, 2025
* Reorganization Finalized: January 6, 2026
* Delisting Effective Date: January 16, 2026
* Shares Tendered: 195,341,219 (≈ 86.75%)
* Deal Value: Approximately $1.25 billion (All-Stock)

Implications for Former Shareholders

Investors who tendered their shares now hold BioNTech ADS in their portfolios. Those who did not participate in the offer received the economically equivalent consideration through the post-offer reorganization, net of any applicable Dutch withholding tax on dividends.

In a related administrative step, CureVac Merger B.V. has filed for deregistration with the U.S. Securities and Exchange Commission (SEC). Final removal from the SEC register is anticipated 90 days after the submission of the Form 15 document.

The primary outcome is clear: CureVac no longer exists as a standalone listed entity. Its former assets and operations are now entirely consolidated within BioNTech, which is currently evaluating the future organizational and portfolio strategy for the combined enterprise.